

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
















